Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

The UK Coronavirus Cancer Programme, led by Dr Lennard Lee (Department of Oncology), has undertaken a population-scale real-world evaluation of the third dose COVID-19 vaccination booster programme in 361,098 UK patients with cancer. Breakthrough infection, symptomatic infection, COVID-19-associated hospitalisation and death were compared between the cancer cohort and the general population.

The study, published in the European Journal of Cancer, found that vaccine effectiveness was increased in the cancer and population cohorts following the third vaccine dose, but that effectiveness was lower in patients with cancer compared to the general population.

Comparing between patients with different types of cancer, vaccine effectiveness against breakthrough and symptomatic infections was higher following third dose boosters in those with solid organ malignancies compared to patients with haematological cancers, and protection against symptomatic COVID-19 was lowest in patients with lymphoma.

A recent cancer diagnosis or being treated in the last 12 months with chemotherapy or radiotherapy were also associated with lower vaccine effectiveness against breakthrough and symptomatic COVID-19 infections.

The findings from this study highlight the ongoing susceptibility of cancer patients to COVID-19 and would support additional measures to protect this population.

Read more about the study's findings in relation to vaccination effectiveness in cancer patients.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.